Legacy Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$275K	Buy	526 +18	+4%	+$9.22K	0.03%	247
2026 Q2	$252K	Buy	+508	New	+$225K	0.02%	283
2025 Q1	$461K	Buy	951 +62	+7%	+$28.9K	0.05%	272
2024 Q4	$358K	Buy	889 +99	+13%	+$45.9K	0.03%	288
2024 Q3	$367K	Buy	790 +241	+44%	+$116K	0.04%	273
2024 Q2	$257K	Buy	549 +2	+0.4%	+$868	0.03%	273
2024 Q1	$229K	Buy	547 +33	+6%	+$14K	0.03%	285
2023 Q4	$209K	Buy	+514	New	+$190K	0.03%	293
2019 Q2	–	Sell	-8,000	Closed	-$1.47M	–	425
2019 Q1	$1.47M	Buy	+8,000	New	+$1.48M	0.48%	49
2017 Q4	–	Sell	-67	Closed	-$10K	–	433
2017 Q3	$10K	Buy	+67	New	+$10.1K	0.01%	225

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Legacy Advisors's VRTX Position: Q3 2026 in Review

Legacy Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q3 2026, buying an estimated $9.22K and bringing the position to 526 shares worth $275K. The position accounts for 0.03% of the portfolio, ranked #247.

Legacy Advisors first reported a position in VRTX in Q3 2017 and has held it in 10 quarters since. The position peaked at $1.47M in Q1 2019. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Legacy Advisors held 526 shares of Vertex Pharmaceuticals worth $275K as of Q3 2026.
Legacy Advisors bought 18 Vertex Pharmaceuticals shares in Q3 2026, an estimated $9.22K.
Vertex Pharmaceuticals made up 0.03% of Legacy Advisors's portfolio in Q3 2026, its #247 holding.
Legacy Advisors first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 10 quarters since.
Legacy Advisors's Vertex Pharmaceuticals position peaked at $1.47M in Q1 2019.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Legacy Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.